Last reviewed · How we verify

NCT01355276

A Randomized, Double-blind, Double-dummy, Active Drug Parallel Controlled, Multi-center Clinical Trial on the Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Completed Phase 3 Last updated 29 November 2011
What this trial tests

Phase 3 trial testing Cinitapride in Dyspepsia in 400 participants. Completed in 1 October 2011.

Timeline
1 October 2010
Primary endpoint
1 June 2011
1 October 2011

Quick facts

Lead sponsorEisai China Inc.
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment400
Start date1 October 2010
Primary completion1 June 2011
Estimated completion1 October 2011
Sites13 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Eisai China Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Dyspepsia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to compare Cinitapride tablets with domperidone tablets (motilium), and to evaluate the efficacy and safety of Cinitapride tablets in the treatment of mild to moderate functional dyspepsia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dyspepsia

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01355276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing